DrugPatentWatch® Litigation and Generic Entry Outlook for Xtandi.
A generic version of XTANDI was approved as enzalutamide by APOTEX on April 22nd, 2022.
Nubeqa aka Darolutamide will be eligible for patent challenges on July 30, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
this is very good news!!